Genentech’s IPF Therapy to Improve Lung Function
New data from Phase 3 clinical studies of Genentech’s Esbriet (pirfenidone), a drug developed for the treatment of pulmonary fibrosis (PF), showed the treatment’s efficacy over time.
The data presentation, the “Effect of continued treatment with pirfenidone following a clinically meaningful decline in percent predicted forced vital capacity in patients with idiopathic pulmonary fibrosis (IPF),” was made by Dr. Steven Nathan, Medical Director of the Advanced Lung Disease and Transplant Program at Inova Fairfax Hospital, at the Pulmonary Fibrosis Foundation’s recent PFF Summit 2015, held in Washington, D.C.
About the Author
